Skip to main content
SpringerLink
Log in

Tibolone labelling to provide cancer, CV risk info

  • News item
  • Published:
Reactions Weekly Aims and scope

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

REFERENCE

  1. EMA Pharmacovigilance Working Party (PhVWP).Tibolone - risk of venous thromboembolism, myocardial infarction, breast cancer and ovarian cancer. PhVWP Monthly Report: 3 [+ Annex 4], No. 1111, 24 Nov 2011

  2. Danish Medicines Agency.Tibolone and a potential risk of thromboembolisms, myocardial infarction, breast cancer and ovarian cancer. Danish Pharmacovigilance Update 2: 3, No. 12, 15 Dec 2011. Available from: URL: http://laegemiddelstyrelsen.dk

Download references

Rights and permissions

Reprints and permissions

About this article

Cite this article

Tibolone labelling to provide cancer, CV risk info. React. Wkly. 1385, 5 (2012). https://doi.org/10.2165/00128415-201213850-00011

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00128415-201213850-00011

Keywords

Search

Navigation